PABLO DE LA
CUEVA DOBAO
Profesor asociado
Complexo Hospitalario Universitario de Vigo
Vigo, EspañaPublicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Vigo (21)
2024
-
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363
2023
-
Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 8, pp. 1587-1594
-
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)
Actas Dermo-Sifiliograficas
-
[Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T479-T487
2022
-
Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS
Dermatology, Vol. 238, Núm. 2, pp. 320-328
-
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis
JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572
-
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406
-
Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer –Basal Cell Carcinoma or Squamous Cell Carcinoma-Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 5, pp. 451-458
-
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry
Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117
-
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population
Journal of the European Academy of Dermatology and Venereology
2021
-
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis
Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517
2020
-
Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760
-
Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project
Reumatologia Clinica, Vol. 16, Núm. 1, pp. 24-31
-
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150
-
The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741
2019
-
Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study
Journal of Dermatological Treatment, Vol. 30, Núm. 5, pp. 461-465
2018
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800
-
Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals
Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 631-642
2017
-
Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts
British Journal of Dermatology, Vol. 176, Núm. 3, pp. 643-649
2016
-
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209